BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Narayanan N, Naik D, Sahoo J, Kamalanathan S. Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control. World J Virol 2022; 11(6): 399-410 [PMID: 36483108 DOI: 10.5501/wjv.v11.i6.399]
URL: https://www.wjgnet.com/2220-3249/full/v11/i6/399.htm
Number Citing Articles
1
Ewa Pius-Sadowska, Piotr Kulig, Anna Niedźwiedź, Bartłomiej Baumert, Karolina Łuczkowska, Dorota Rogińska, Anna Sobuś, Zofia Ulańczyk, Miłosz Kawa, Edyta Paczkowska, Miłosz Parczewski, Anna Machalińska, Bogusław Machaliński. VEGFR and DPP-IV as Markers of Severe COVID-19 and Predictors of ICU AdmissionInternational Journal of Molecular Sciences 2023; 24(23): 17003 doi: 10.3390/ijms242317003
2
Bianca Pari, Matteo Gallucci, Alberto Ghigo, Maria Felice Brizzi. Insight on Infections in Diabetic SettingBiomedicines 2023; 11(3): 971 doi: 10.3390/biomedicines11030971
3
Jelena Dimnjaković, Tamara Buble, Pero Ivanko, Tamara Poljičanin, Sandra Karanović Štambuk, Hana Brborović, Ognjen Brborović, Timotius Ivan Hariyanto. Association of anti-diabetic drugs and covid-19 outcomes in patients with diabetes mellitus type 2 and chronic kidney disease: Nationwide registry analysisPLOS ONE 2024; 19(3): e0301056 doi: 10.1371/journal.pone.0301056
4
Klara R. Klein, Trine J. Abrahamsen, Anna R. Kahkoska, G. Caleb Alexander, Christopher G. Chute, Melissa Haendel, Stephanie S. Hong, Hemalkumar Mehta, Richard Moffitt, Til Stürmer, Kajsa Kvist, John B. Buse. Association of Premorbid GLP-1RA and SGLT-2i Prescription Alone and in Combination with COVID-19 SeverityDiabetes Therapy 2024; 15(5): 1169 doi: 10.1007/s13300-024-01562-1
5
D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, A. V. Strygin, Yu. V. Gorbunova, E. V. Volotova, I. E. Makarenko, V. B. Saparova, R. V. Drai, V. I. Petrov. Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors usePharmacy & Pharmacology 2023; 11(1): 19 doi: 10.19163/2307-9266-2023-11-1-19-47